NAPRELAN Drug Patent Profile

When do Naprelan patents expire, and when can generic versions of Naprelan launch?

Naprelan is a drug marketed by Twi Pharms and is included in one NDA.

The generic ingredient in NAPRELAN is naproxen sodium. There are forty-two drug master file entries for this compound. One hundred and twenty-nine suppliers are listed for this compound. Additional details are available on the naproxen sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Naprelan

A generic version of NAPRELAN was approved as naproxen sodium by CONTRACT PHARMACAL on January 13^th, 1997.

Summary for NAPRELAN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	8
Patent Applications:	7,098
Drug Prices:	Drug price information for NAPRELAN
Drug Sales Revenues:	Drug sales revenues for NAPRELAN
What excipients (inactive ingredients) are in NAPRELAN?	NAPRELAN excipients list
DailyMed Link:	NAPRELAN at DailyMed

See drug prices for NAPRELAN

See drug sales revenues for NAPRELAN

Recent Clinical Trials for NAPRELAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Northwestern Medical Group	Phase 2
Apkar Apkarian	Phase 4
Northwestern University	Phase 4

See all NAPRELAN clinical trials

Pharmacology for NAPRELAN

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for NAPRELAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-001	Jan 5, 1996	AB	RX	Yes	No
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-002	Jan 5, 1996	AB	RX	Yes	No
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-003	Jan 5, 1996	AB	RX	Yes	Yes

Expired US Patents for NAPRELAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-001	Jan 5, 1996
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-003	Jan 5, 1996
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-002	Jan 5, 1996

International Patents for NAPRELAN

See the table below for patents covering NAPRELAN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	126055
Australia	639519
Australia	6933291
Canada	2034096	FORMULATION DE NAPROXENE A LIBERATION CONTROLEE POUR ADMINISTRATION UNE FOIS PAR JOUR (CONTROLLED ABSORPTION NAPROXEN FORMULATION FOR ONCE-DAILY ADMINISTRATION)
Germany	69111832
Denmark	0438249
European Patent Office	0438249	Formule de naproxen à absorption controlée pour l'administration une fois par jour. (Controlled absorption naproxen formulation for once-daily administration.)

Supplementary Protection Certificates for NAPRELAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1411900	C300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957	PA2011005,C0984957	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105

NAPRELAN (naproxen sodium) Market Dynamics and Financial Trajectory: Sales Drivers, Competitive Pressure, and Patent/Generic Timing

Last updated: July 30, 2026

NAPRELAN is the branded extended-release naproxen sodium product (Teva). Its market is shaped by long-running generic displacement, shifting payer formularies for NSAIDs, and patient substitution toward lower-cost naproxen brands and competitive ER options. Financial trajectory is dominated by declining branded pricing power, share erosion versus multisource generics, and periodic upticks tied to competitive changes and contract cycles rather than new exclusivity.

---

How has NAPRELAN performed financially versus generic naproxen and other NSAIDs?

Answer: NAPRELAN’s financial trajectory is consistent with a mature NSAID brand facing sustained generic pricing compression. In the absence of current, date-stamped revenue data in the provided input, the market dynamic is best read through structural forces: multigenerics in ER naproxen, buyer behavior on NSAIDs, and contract-driven switching to lowest net cost.

What drives NAPRELAN revenue in a mature NSAID market?

1. Net price compression

   • Branded ER NSAIDs typically lose the spread as generic ER naproxen proliferates and payers narrow coverage to formulary-preferred products.
   • NAPRELAN competes on total cost of therapy: copays, adherence, and payer step edits often outweigh brand-level differentiation.

2. Formulary and rebate dynamics

   • NSAID use is high-volume and frequently managed through tiering.
   • Contracting frequently prioritizes the lowest WAC-to-net-cost mix among ER NSAID options.

3. Patient substitution and therapy switching

   • Many patients and prescribers tolerate switching among equivalent naproxen sodium ER products unless controlled by specific prescriber preference or intolerance patterns.

4. Safety and risk management

   • NSAID boxed warning risk considerations and GI/cardiovascular risk profiles can influence prescribing patterns toward alternative NSAIDs or COX-2 selective options, shrinking the addressable ER naproxen pool.

How does the commercial mix likely split by indication?

NAPRELAN’s positioning has historically covered musculoskeletal and inflammatory pain indications typical for naproxen sodium ER. In practice, sales tend to correlate with:

• Arthritis-related chronic use (long persistence early, then gradual leakage to generics)
• Acute flare use patterns that favor readily available generics
• Payer policies that restrict or steer NSAID selection

---

What market dynamics determine NAPRELAN sales today?

Answer: The dominant determinants are generic-led price competition, payer formulary behavior, and ER NSAID switching economics.

Payer and channel mechanics that pressure branded NSAIDs

• Therapeutic class grouping: NSAIDs are treated as interchangeable at the payer tier level, limiting branded differentiation.
• Switching behavior: ER naproxen dosing convenience is real, but it is not a moat if multiple ER naproxen SKUs meet formulary rules.
• Gross-to-net degradation: Brand competitiveness in mature NSAIDs depends on rebate intensity to maintain tier placement; this reduces profitability even if units persist.

Regulatory and safety factors that shape utilization

• Label risk context: NSAIDs carry class warnings that shift provider risk tolerance.
• COX-2 and alternative NSAID competition: In some formularies, alternative NSAIDs or topical agents can substitute, reducing the pool of oral ER NSAID users.

---

What generic or biosimilar threats exist for NAPRELAN and how do they affect pricing?

Answer: The threat is almost entirely generic substitution (small-molecule). “Biosimilar” risk is not applicable because naproxen sodium is a conventional chemical entity.

Generic threat profile for an ER naproxen sodium brand

• Multisource pressure is structural: ER naproxen sodium is typically supported by multiple abbreviated approvals over time, leaving the brand exposed to continuous price competition.
• Interchangeability at pharmacy level: If payers list multiple AB-rated products, pharmacists fill with the lowest-cost option consistent with reimbursement and patient cost-share rules.
• Margin dilution: Even when NAPRELAN retains a minority share, it often survives only by accepting lower net pricing or higher rebates.

---

When does NAPRELAN lose exclusivity and what does that mean for launch timing of competitors?

Answer: NAPRELAN is a long-established product; its key exclusivity windows have long since expired. The practical implication is ongoing generic availability and “incremental” competition cycles driven by additional ANDA approvals, labeling carve-outs, and ER formulation patent cliffs that occurred historically.

How exclusivity cliffs typically show up in sales for mature NSAIDs

• Pre-cliff: Stable units with rebate investment to maintain preferred status.
• Cliff period: Unit and share step-down as multiple AB-rated generics enter.
• Post-cliff: Brand persists only if it maintains a formulary position via net pricing, contracting, or restricted coverage exceptions.

---

What is the Orange Book status of NAPRELAN and how many patents cover it?

Answer: Orange Book patent coverage is the controlling document for AB-rated competitors and any Paragraph IV litigation risk, but the required Orange Book listings and patent counts are not contained in the provided input. Without those specifics, the patent landscape cannot be stated accurately here.

---

Which patents protect NAPRELAN’s extended-release formulation and method of use?

Answer: The provided input does not include NAPRELAN’s Orange Book patent numbers, assignees, claims, or expiration dates. Without those data points, protection scope cannot be listed without risk of inaccuracy.

---

What patent litigation affects NAPRELAN and what settlement agreements changed market outcomes?

Answer: No case captions, court outcomes, or settlement terms are included in the provided input. Litigation and settlement history cannot be cited or summarized reliably.

---

How strong is the patent estate for NAPRELAN versus generic entrants?

Answer: Patent strength is not quantifiable from the provided input. Without the relevant Orange Book patent inventory and expiration/active claim status, comparative strength cannot be assessed.

---

What formulation and dosage forms matter for NAPRELAN competition (ER tablet variants, dosing, and strengths)?

Answer: NAPRELAN is an extended-release naproxen sodium tablet product. Competitive dynamics depend on:

• Strength coverage: Whether competitors launch the same strength set for payer substitution.
• Bioequivalence and release profile: ER performance can influence prescriber switching, but market rules typically still allow substitution among AB-rated ER products.
• Tablet handling and adherence: Small differences may matter in stubborn subpopulations, but the broader market is payer-led.

---

How does NAPRELAN compare with other ER naproxen sodium products and competing NSAID brands?

Answer: NAPRELAN competes against:

• Generic ER naproxen sodium products (primary substitution threat)
• Other ER NSAIDs (secondary substitution depending on formulary design)
• Topical NSAIDs and alternative pain management where formularies steer away from oral NSAID risk

Competitive comparison lens used by payers and PBMs

• Net cost at preferred tier
• Prior authorization requirements
• Step therapy and quantity limits
• Claim history and clinical pathway alignment

---

Where does NAPRELAN derive revenue concentration risk (channels, geographies, and payer segments)?

Answer: Revenue concentration risk is typically highest in:

• Managed care segments where branded share survives through rebate-driven placement
• Geographies where generic penetration is already high and contract cycles periodically reduce net reimbursement spreads
• Institutional formularies (if NAPRELAN retained any preferred status historically, it is usually vulnerable to contract renegotiations)

Because no segment revenue data are provided, the only defensible statement is that branded NSAID products generally experience the largest exposure to payer contract renegotiations after generic proliferation.

---

What generic entry scenarios could still impact NAPRELAN share?

Answer: Even after widespread generic entry, remaining share can be affected by:

• Launch of additional ER strength SKUs under AB-rated pathways
• Label changes that alter substitution rules or require pharmacy-specific clinical review
• Contracting outcomes that switch preferred status away from a brand to another generic or another branded alternative

These are incremental and driven by market access, not by a new exclusivity event.

---

What commercial metrics should be monitored to track NAPRELAN’s trajectory going forward?

Answer: For a mature, generic-exposed branded NSAID, the key leading indicators are market access and unit-level continuity.

Monitoring checklist

• Net sales trend (quarterly) and gross-to-net ratio
• TRx share versus the dominant AB-rated ER naproxen sodium generics
• Formulary tiering changes and PBM preferred status updates
• Rebate rate movement tied to contract renewals
• Price corridor: average selling price relative to key generic comparators
• WAC-to-net spread compression signaling continued erosion of pricing power

---

Key Takeaways

• NAPRELAN’s financial trajectory is shaped by generic ER naproxen sodium penetration and payer-led switching economics rather than by new exclusivity.
• The market is structurally exposed to ongoing net price pressure, with stability at the unit level possible only through rebate-driven formulary retention.
• Patent and litigation-driven “entry cliffs” likely occurred historically; current market outcomes are primarily contract and formulary driven.
• Forward visibility depends on TRx and payer positioning metrics more than on brand marketing or product lifecycle novelty.

---

FAQs

1. Is NAPRELAN at risk of biosimilar competition?
   No. Naproxen sodium is a small-molecule drug; the competitive risk is generic substitution.

2. What drives NAPRELAN performance when branded NSAID unit demand is steady?
   Gross-to-net compression, rebate changes, and formulary tier placement typically determine whether revenue holds or erodes.

3. Do ER naproxen sodium generics usually compete at the same strengths as NAPRELAN?
   Competitive impact is strongest when generics cover the same ER strength set and are AB-rated for substitution within payer rules.

4. How do prior authorization and step therapy affect NAPRELAN?
   They can reduce access and shift prescribers and pharmacies toward formulary-preferred alternatives or lower-cost generics.

5. What is the best indicator of future NAPRELAN share change?
   PBM preferred listing updates and TRx share movements versus the dominant ER naproxen sodium generic SKUs.

---

References (APA)

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). U.S. Food and Drug Administration.